The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug discovery purposes, among other uses. Now, scientists at the Arc Institute have created Evo, an AI model that generates DNA sequences and estimates their interaction with other molecules at single-nucleotide resolution, scalable to an entire genome.
While women make up half the world’s population and own two out of every five businesses, there are substantial knowledge gaps about conditions affecting their health – mostly due to decades of research excluding women from clinical trials and investment decisions.
EA Pharma Co. Ltd. has described 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors reported to be useful for the treatment of age-related issues, as well as inflammatory, metabolic, neurodegenerative, mitochondrial and renal diseases.
Evotec International GmbH has synthesized integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.
Kalvista Pharmaceuticals Ltd. has identified coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of hereditary angioedema, atherosclerosis, inflammatory disorders, neurodegeneration, diabetic retinopathy, SARS-CoV-2 infection (COVID-19), stroke and thrombotic disorders, among others.
MDX-2001 (Modex Therapeutics Inc.) was engineered as a potentially first-in-class tetraspecific lymphocyte activator and survival enhancement receptor (LASER) recognizing CD3 and CD28 on human T cells and c-MET and TROP2 on tumor cells.
DEAD-box helicase 17 (DDX17) is an RNA helicase involved in the early phases of neuronal differentiation. Researchers have identified a total of 13 patients presenting with neurodevelopmental phenotypes and who harbored de novo monoallelic variants in the DDX17 gene. The phenotype was characterized by intellectual disability, delayed speech and language, as well as motor delay.
Genetic alterations in FAT1, YAP1 or WWTR1 genes are commonly seen in head and neck squamous cell carcinoma (HNSCC) patients. Targeting Hippo and MAPK pathways in combination has proven effective in preclinical models of HNSCC.